← Leaderboards
Frank I Carroll
Research Triangle Institute
$18,291,450
Attributed
$18,291,450
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.3M · FY2005–14$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$28,089,702 · 14
By mechanism
R01$12,018,436 · 4
U19$11,585,405 · 8
R37$3,410,371 · 1
U09$1,075,490 · 1
Top collaborators
No co-investigators on record.
Most similar at Research Triangle Institute
Same institution · by research overlap
- James L Howard$495,829
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogCocainePharmacotherapyPharmaceutical PreparationsPropertyBinding (Molecular Function)LeadDesignReceptorProgramsGrantRattusBaseDrug Design /Synthesis /ProductionLigandsIn VitroReceptor BindingIn VivoEvaluationDependenceBrainNicotinic ReceptorsAddictionDrug Abuse
Grant awards (70)
Selective Opioid Antagonists as Medications for Drug Abuse$392,672
R01 · FY2014 · DA · contact PI
Selective Opioid Antagonists as Medications for Drug Abuse$376,894
R01 · FY2013 · DA · contact PI
Development of Ligands for Nicotinic Receptors$412,931
R01 · FY2012 · DA · contact PI
Selective Opioid Antagonists as Medications for Drug Abuse$392,440
R01 · FY2012 · DA · contact PI
Development of Ligands for Nicotinic Receptors$413,058
R01 · FY2011 · DA · contact PI
Selective Opioid Antagonists as Medications for Drug Abuse$392,337
R01 · FY2011 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$184,256
U19 · FY2011 · DA · contact PI
Administrative Core$64,811
U19 · FY2011 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$825,297
U19 · FY2010 · DA · contact PI
Design and Development of Pharmacotherapies for Treating Stimulant Abuse$479,869
R01 · FY2010 · DA · contact PI
Development of Ligands for Nicotinic Receptors$426,174
R01 · FY2010 · DA · contact PI
Selective Opioid Antagonists as Medications for Drug Abuse$404,501
R01 · FY2010 · DA · contact PI
Administrative Core$106,158
U19 · FY2010 · DA · contact PI
Development of Pharmacotherapies for Nicotine Addiction$704,648
U19 · FY2009 · DA · contact PI
Design and Development of Pharmacotherapies for Treating Stimulant Abuse$475,158
R01 · FY2009 · DA · contact PI
Development of Ligands for Nicotinic Receptors$431,656
R01 · FY2009 · DA · contact PI
Development of Ligands for Nicotinic Receptors$212,181
R01 · FY2009 · DA · contact PI
Synthesis of Bupropion Analogs, Including Possible Metabolites and 3-Phenyltropan$188,223
U19 · FY2009 · DA · contact PI
Administrative Core$124,387
U19 · FY2009 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$62,865
U19 · FY2009 · DA · contact PI
Development of Pharmacotherapies for Nicotine Addiction$684,804
U19 · FY2008 · DA · contact PI
Development of Ligands for Nicotinic Receptors$430,199
R01 · FY2008 · DA · contact PI
Selective Opioid Antagonist as Medication for Drug Abuse$427,956
R01 · FY2008 · DA · contact PI
Administrative Core$170,663
U19 · FY2008 · DA · contact PI
Synthesis of Bupropion Analogs, Including Possible Metabolites and 3-Phenyltropan$167,871
U19 · FY2008 · DA · contact PI
NOVEL PHARMACOTHERAPY FOR TREATMENT OF COCAINE ADDICTION$74,880
U19 · FY2008 · DA · contact PI
Development of Pharmacotherapies for Nicotine Addiction$696,346
U19 · FY2007 · DA · contact PI
NOVEL PHARMACOTHERAPY FOR TREATMENT OF COCAINE ADDICTION$650,551
U19 · FY2007 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$566,743
U19 · FY2007 · DA · contact PI
Selective Opioid Antagonist as Medication for Drug Abuse$437,396
R01 · FY2007 · DA · contact PI
Administrative Core$225,641
U19 · FY2007 · DA · contact PI
COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION$156,322
R37 · FY2007 · DA · contact PI
Synthesis of Bupropion Analogs, Including Possible Metabolites and 3-Phenyltropan$153,686
U19 · FY2007 · DA · contact PI
Administrative Core$115,114
U19 · FY2007 · DA · contact PI
DRUG SYNTHESIS % TREATMENT FOR COCAINE ADDICTION$108,424
U19 · FY2007 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$715,572
U19 · FY2006 · DA · contact PI
Development of Pharmacotherapies for Nicotine Addiction$688,792
U19 · FY2006 · DA · contact PI
Selective Opioid Antagonist as Medication for Drug Abuse$451,051
R01 · FY2006 · DA · contact PI
Development of Ligands for Nicotinic Receptors$413,500
R01 · FY2006 · DA · contact PI
Kappa Opioid Antagonist for Cocaine Addiction$828,095
U19 · FY2005 · DA
Development of Pharmacotherapies for Nicotine Addiction$649,807
U19 · FY2005 · DA
COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION$586,582
R37 · FY2005 · DA
Selective Opioid Antagonist as Medication for Drug Abuse$462,531
R01 · FY2005 · DA
Development of Ligands for Nicotinic Receptors$414,032
R01 · FY2005 · DA
Administrative Core$362,175
U19 · FY2005 · DA
COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION$569,503
R37 · FY2004 · DA
Selective Opioid Antagonist as Medication for Drug Abuse$463,268
R01 · FY2004 · DA
Development of Ligands for Nicotinic Receptors$404,901
R01 · FY2004 · DA
COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION$552,916
R37 · FY2003 · DA
Development of Ligands for Nicotinic Receptors$395,983
R01 · FY2003 · DA
SELECTIVE OPIOID ANTAGONIST AS MEDICATION FOR DRUG ABUSE$361,624
R01 · FY2003 · DA
SCIENTIFIC EVALUATION$254,000
U09 · FY2003 · DA
NOVEL PHARMACOTHERAPY FOR TREATMENT OF COCAINE ADDICTION$752,608
U19 · FY2002 · DA
COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION$556,663
R37 · FY2002 · DA
Development of Ligands for Nicotinic Receptors$359,886
R01 · FY2002 · DA
SELECTIVE OPIOID ANTAGONIST AS MEDICATION FOR DRUG ABUSE$351,104
R01 · FY2002 · DA
SCIENTIFIC EVALUATION$175,000
U09 · FY2002 · DA
SCIENTIFIC EVALUATION$80,000
U09 · FY2002 · DA
NOVEL PHARMACOTHERAPY FOR TREATMENT OF COCAINE ADDICTION$909,976
U19 · FY2001 · DA
COCAINE: A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION$521,147
R37 · FY2001 · DA
SELECTIVE OPIOID ANTAGONIST AS MEDICATION FOR DRUG ABUSE$339,197
R01 · FY2001 · DA
NOVEL PHARMACOTHERAPIES FOR COCAINE DEPENDENCE$324,638
R01 · FY2001 · DA
SCIENTIFIC EVALUATION$250,000
U09 · FY2001 · DA
DEVELOPMENT OF LIGANDS FOR NICOTINIC RECEPTORS$247,965
R01 · FY2001 · DA
NOVEL PHARMACOTHERAPY FOR TREATMENT OF COCAINE ADDICTION$803,012
U19 · FY2000 · DA
COCAINE--A STUDY OF THE BIOCHEMICAL MECHANISM OF ACTION$467,238
R37 · FY2000 · DA
SELECTIVE OPIOID ANTAGONIST AS MEDICATION FOR DRUG ABUSE$330,930
R01 · FY2000 · DA
SCIENTIFIC EVALUATION$316,490
U09 · FY2000 · DA
NOVEL PHARMACOTHERAPIES FOR COCAINE DEPENDENCE$315,782
R01 · FY2000 · DA
DEVELOPMENT OF LIGANDS FOR NICOTINIC RECEPTORS$276,622
R01 · FY2000 · DA